Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00274599
Status:
COMPLETED
Last Update Posted:
2023-12-06
First Post:
2006-01-10
Brief Title:
PROBE Investigation of the Safety Efficacy of Telmisartan Micardis vs Ramipril Altace Using ABPM in HTN
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Prospective Randomised Open-Label Blinded-Endpoint Parallel Group Multicentre Forced-Titration 14-Week Treatment Study Comparing MICARDIS Telmisartan 40-80-80 mg QD and ALTACE Ramipril 25-5-10 mg QD in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None